Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial.
Hickish T, Mehta A, Liu MC, Huang CS, Arora RS, Chang YC, Yang Y, Vladimirov V, Jain M, Tsang J, Pemberton K, Sadrolhefazi B, Jin X, Tseng LM. Hickish T, et al. Among authors: pemberton k. Breast Cancer Res Treat. 2022 Apr;192(3):593-602. doi: 10.1007/s10549-021-06449-4. Epub 2022 Feb 9. Breast Cancer Res Treat. 2022. PMID: 35138529 Free PMC article. Clinical Trial.
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. O'Brien MER, et al. Among authors: pemberton k. Cancer Chemother Pharmacol. 2018 Nov;82(5):757-766. doi: 10.1007/s00280-018-3661-1. Epub 2018 Aug 7. Cancer Chemother Pharmacol. 2018. PMID: 30088048 Free PMC article. Clinical Trial.
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Spicer J, Irshad S, Ang JE, Enting D, Kristeleit R, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J. Spicer J, et al. Among authors: pemberton k. Cancer Chemother Pharmacol. 2017 Jan;79(1):17-27. doi: 10.1007/s00280-016-3189-1. Epub 2016 Nov 21. Cancer Chemother Pharmacol. 2017. PMID: 27872953 Free PMC article. Clinical Trial.
Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
Saran F, Welsh L, James A, McBain C, Gattamaneni R, Jefferies S, Harris F, Pemberton K, Schaible J, Bender S, Cseh A, Brada M. Saran F, et al. Among authors: pemberton k. J Neurooncol. 2021 Dec;155(3):307-317. doi: 10.1007/s11060-021-03877-6. Epub 2021 Nov 17. J Neurooncol. 2021. PMID: 34787778 Free PMC article. Clinical Trial.
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. Suder A, et al. Among authors: pemberton k. Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18. Eur J Cancer. 2015. PMID: 26296295 Clinical Trial.
77 results